Literature DB >> 8768713

Effects of a memory-enhancing drug on DL-alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor currents and synaptic transmission in hippocampus.

A Arai1, M Kessler, G Rogers, G Lynch.   

Abstract

The benzoylpiperidine drug BDP-12 (1-(quinoxalin-6-ylcarbonyl)piperidine) enhances the encoding of transient and stable forms of memory by rats. Results reported here show that the drug increases fast, excitatory (glutamatergic) synaptic responses in hippocampal slices by about 50% with an EC50 of 170 microM. Analyses with polysynaptic responses indicated that the drug has a facilitatory action at concentrations as low as 12.5 microM. BDP-12 at 1 mM did not change the resting membrane potential, input resistance or spiking threshold and it did not alter monosynaptic potentials mediated by gamma-aminobutyric acid (GABA) receptors; it did, however, enhance disynaptic inhibitory responses. In membrane patches excised from hippocampal neurons, BDP-12 at moderate concentrations (50 microM) increased the steady-state currents mediated by DL-alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors and slowed the rate at which the receptors desensitize, with a much larger effect on the former; the drug delayed the closing of the AMPA receptor channel after 1-msec agonist pulses. BDP-12 had no detectable effect on [3H]AMPA binding affinity. A related and more potent analog produced a different pattern of results in that it had about equal effects on steady-state currents and desensitization rates and significantly increased binding to AMPA receptors. These results indicate that the benzoylpiperidine family of modulators has functionally distinct subclasses. The findings also establish that BDP-12: 1) enhances synaptic responses in the same concentration range at which it alters AMPA receptor kinetics, 2) has a lower apparent threshold for effects on complex network operations than on monosynaptic transmission, 3) does not directly influence inhibitory responses and 4) is likely to modulate AMPA receptors on interneurons as well as on pyramidal neurons.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8768713

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  26 in total

1.  AMPA receptor facilitation accelerates fear learning without altering the level of conditioned fear acquired.

Authors:  M T Rogan; U V Stäubli; J E LeDoux
Journal:  J Neurosci       Date:  1997-08-01       Impact factor: 6.167

2.  A desensitization-selective potentiator of AMPA-type glutamate receptors.

Authors:  Masayuki Sekiguchi; Kaori Nishikawa; Shunsuke Aoki; Keiji Wada
Journal:  Br J Pharmacol       Date:  2002-08       Impact factor: 8.739

Review 3.  Potential therapeutic interventions for fragile X syndrome.

Authors:  Josien Levenga; Femke M S de Vrij; Ben A Oostra; Rob Willemsen
Journal:  Trends Mol Med       Date:  2010-09-21       Impact factor: 11.951

Review 4.  Therapeutic potential of positive AMPA receptor modulators in the treatment of neuropsychiatric disorders.

Authors:  Stefano Marenco; Daniel R Weinberger
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

5.  Glutamate receptor-mediated restoration of experience-dependent place field expansion plasticity in aged rats.

Authors:  Sara N Burke; Andrew P Maurer; Zhiyong Yang; Zaneta Navratilova; Carol A Barnes
Journal:  Behav Neurosci       Date:  2008-06       Impact factor: 1.912

6.  AMPAkines have novel analgesic properties in rat models of persistent neuropathic and inflammatory pain.

Authors:  Alexander M Le; Michelle Lee; Chen Su; Anthony Zou; Jing Wang
Journal:  Anesthesiology       Date:  2014-11       Impact factor: 7.892

7.  Positive modulation of AMPA receptors increases neurotrophin expression by hippocampal and cortical neurons.

Authors:  J C Lauterborn; G Lynch; P Vanderklish; A Arai; C M Gall
Journal:  J Neurosci       Date:  2000-01-01       Impact factor: 6.167

8.  Changes in AMPA receptor-spliced variant expression and shift in AMPA receptor spontaneous desensitization pharmacology during cerebellar granule cell maturation in vitro.

Authors:  P Longone; F Impagnatiello; J M Mienville; E Costa; A Guidotti
Journal:  J Mol Neurosci       Date:  1998-08       Impact factor: 3.444

9.  A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia.

Authors:  Donald C Goff; J Steven Lamberti; Andrew C Leon; Michael F Green; Alexander L Miller; Jayendra Patel; Theo Manschreck; Oliver Freudenreich; Steven A Johnson
Journal:  Neuropsychopharmacology       Date:  2007-05-09       Impact factor: 7.853

10.  Opiate-induced suppression of rat hypoglossal motoneuron activity and its reversal by ampakine therapy.

Authors:  Amanda R Lorier; Gregory D Funk; John J Greer
Journal:  PLoS One       Date:  2010-01-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.